<DOC>
	<DOC>NCT00219271</DOC>
	<brief_summary>The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer</brief_summary>
	<brief_title>Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Criteria Prostate cancer Radical prostatectomy or external beam irradiation therapy within 6 months before study entry. No bone metastases according to bone scan Exclusion Criteria Metastatic prostate cancer Hormone ablation therapy for more than 3 months before/after radical prostatectomy and external beam irradiation therapy Treatment with bisphosphonates or other drugs known to affect the skeleton within the past year. Other protocoldefined inclusion / exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>molecular staging</keyword>
	<keyword>antitumor potential</keyword>
</DOC>